Abstract
: Based on the concept of “Enteric Dialysis®” Kibow Biotech’s proprietary patented kidney health supplement, has proven helpful in many suffering from CKD, for healthy kidney function by gut microbiome modulation. Available since 2010, it is continually being studied to assess its effectiveness. This survey was to evaluate GFR changes as measured in mL/min per 1.73 m2 , and quality of life (QoL) improvements in customers taking this synbiotic dietary supplement along with their standard care of therapy. Methods: A survey was distributed to 600 customers taking this product. Questions included GFR before taking this supplement, and at their most recent doctor’s visit, age, race, ethnicity, and QoL. GFR data and QoL was analyzed statistically. 214 (35%) survey responses were received. Results: The average survey participant was 69 years and using this proprietary supplement for 2.05 years. 150 surveys contained complete information, including GFR. Baseline GFR was 4 to 100 with an average of 29. The most recent GFR varied from 5 to 102. The highest impact on GFR was an increase of 65, and the largest decrease in GFR was -43. The average change in GFR for a survey participant was an increase of 3.55 mL/min/1.73 m² . 88% of survey participants reported this product improved their QoL. Conclusion: CKD is generally recognized as a degenerative process. With over 4,000 customers using this pro/prebiotic patented dietary supplement we sought feedback from 15% to assess its impact over an average use of 2.05 years. The longest usage of the product was 7 years, the shortest-6 months. With the ability to stabilize and improve GFR, it may be possible to delay all stages of kidney failure progression. Improved QoL in 88% of participants certainly signifies the advantages of using this patented supplement in patients with compromised renal function worldwide. Keywords:
Cite
CITATION STYLE
N, R., U, V., K, H., P, R., A, I., A, W., & EA, F. (2018). Improvements in Glomerular Filtration Rate (GFR) in Chronic Kidney Disease (CKD) Patients Using a Commercial Patented and Proprietary ProbioticPrebiotic Formulation* -3rd Biennial Survey. International Journal of Nephrology and Kidney Failure, 4(1). https://doi.org/10.16966/2380-5498.154
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.